Image Credit: STAT News
STAT+: BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work
BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction.